Intravitreal Dexamethason treatment of bacterial endophthalmitis.
- Conditions
- Endophthalmitis
- Registration Number
- NL-OMON28649
- Lead Sponsor
- Het Oogziekenhuis Rotterdam
- Brief Summary
indstedt EW, Bennebroek CA, van der Werf DJ, Veckeneer M, Norel AO, Nielsen CC, Wubbels RJ, van Dissel JT, van Meurs JC. A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefes Arch Clin Exp Ophthalmol. 2014; 252(10): 1631-1637. Manning S, Ugahary LC, Lindstedt EW, Wubbels RJ, van Dissel JT, Jansen JTG, Gan I, van Goor AT, Bennebroek CA, van der Werf DJ, Ossewaarde-van Norel A, Mayland Nielsen CC, Tilanus M, van den Biesen PR, Schellekens PA, La Heij E, Faridpooya K, van Overdam K, Veckeneer M, van Meurs JC. A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmol. 2018; 96(4): 348-355. van Meurs JC, van Dissel JTJ. Another perspective on the treatment of postoperative endophthalmitis: Unclear evidence for the role of vitrectomy. Acta Ophthalmol. 2018; 96(8): e1042-e1043.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
1. Post-cataract bacterial endophthalmitis;
2. Strong, and increasing, irritation of anterior chamber and/or vitreous during postoperative 8 weeks interval.
Antibiotics treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vision (ETDRS) after 3, 6 and 12 months,<br>panbacterial PCR.
- Secondary Outcome Measures
Name Time Method